Merck KGaA, Darmstadt, Germany, Acquires OLED Patents for Display Applications from Konica Minolta
- Merck KGaA, Darmstadt, Germany, acquires more than 700 patent families for OLED display applications from Konica Minolta.
- Acquired IP will further enhance the company’s position as key supplier of OLED materials.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it acquired the OLED patent portfolio for display applications from Konica Minolta Inc., a global technology company that provides innovative solutions to businesses and society. The acquired portfolio comprises over 700 patent families.
“Adding Konica Minolta’s patents to our already strong portfolio will further boost our OLED development pipeline”, said Kai Beckmann, Member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO Performance Materials. “With this step we will further strengthen our power to drive innovations in the fast-growing market of OLED displays.”
For more than 15 years, Merck KGaA, Darmstadt, Germany has conducted research and development in the OLED technology field, and, as a result, became one of the leading OLED material suppliers.
The acquisition of Konica Minolta’s OLED patents for display applications is effective immediately. Financial terms were not disclosed.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer integrated services